Alamar Biosciences went public barely four months ago - a $17.00 IPO on April 20, 2026 - and the quarter it just reported is the reason the deal priced. This is a precision-proteomics platform claiming it can detect disease earlier than anyone else, built around the NULISA assay technology and the ARGO HT instrument, with Alzheimer's as its beachhead market. The fiscal second quarter was its strongest yet, and the market made its view plain: the shares rose roughly 31% on August 11, the day after results, to touch an intraday high above $38, then settled into the low- to mid-$30s - a stock that has roughly doubled off its $17.00 IPO price in under four months.
The numbers behind the rally are genuinely strong. Revenue grew 82% to $29.4 million, and the mix mattered more than the headline: consumable revenue, the recurring razor-blade half of the model, grew 147% to $15.5 million and now makes up more than half of total sales. Gross margin jumped to 60% from 53% a year ago on manufacturing efficiencies and the richer mix. The company is still unprofitable - an operating loss of $13.5 million and a net loss of $13.2 million, or $0.22 a share - but it raised full-year guidance to $116 million to $120 million, growth of 59% at the midpoint over the prior year, and entered the period with $256.3 million of cash, short-term investments and restricted cash. It also amended its credit facility in August, trading a $10 million term loan and $10 million revolver for a single revolver with up to $100 million of borrowing capacity.
The tension in the stock is not the business; it is the price. At roughly $33 the company trades near a $2.30 billion market capitalization, about 19–20x this year's guided revenue and higher versus a trailing-twelve-month revenue base of roughly $100 million. That is a rich multiple for a company that is still research-use-only, still losing more than $30 million of operating cash flow a half, and running a $116–120 million guide whose continuation to a triple-digit-growth leg is the entire bull case. The quarter proved the model can scale. Whether the multiple buys growth at this price is the question the next several quarters must answer.